The final step in the biosynthesis of fosfomycin in Streptomyces wedmorensis is catalyzed by (S)-2-hydroxypropylphosphonic acid (HPP) epoxidase (Sw-HppE). A homologous enzyme from Pseudomonas syringae has recently been isolated whose encoding gene (orf3) shares relatively low sequence homology to the corresponding Sw-HppE gene. This purified P. syringae protein was determined to catalyze the epoxidation of (S)-HPP to fosfomycin and the oxidation of (R)-HPP to 2-oxopropylphosphonic acid under the same conditions as Sw-HppE. Therefore, this protein is indeed a true HPP epoxidase and is termed Ps-HppE. Like Sw-HppE, Ps-HppE was determined to be posttranslationally modified by the hydroxylation of a putative active site tyrosine (Tyr95). Analysis of the Fe(II)-center by EPR spectroscopy using NO as a spin probe and molecular oxygen surrogate reveals that Ps-HppE's metal center is similar, but not identical, to that of Sw-HppE. The identity of the rate determining step for the (S)-HPP and (R)-HPP reactions was determined by measuring primary deuterium kinetic effects, and the outcome of these results were correlated with density functional theory calculations. Interestingly, the reaction using the non-physiological substrate (R)-HPP was 1.9 times faster than that with (S)-HPP for both Ps-HppE and Sw-HppE. This is likely due to the difference in bond dissociation energy of the abstracted hydrogen atom for each respective reaction. Thus, despite low amino acid sequence identity, Ps-HppE is a close mimic of Sw-HppE, representing a second example of a non-heme iron-dependent enzyme capable of catalyzing dehydrogenation of a secondary alcohol to form a new C-O bond.Fosfomycin (1) is a clinically useful antibiotic (1) for the treatment of limb-threatening diabetic foot infections (2) and lower urinary tract infections. It has been shown to be effective against ciprofloxacin-resistant Escherichia coli (3), as well as methicillin-resistant (4) and vancomycin-resistant (5) strains of Staphylococcus aureus. The antimicrobial activity of fosfomycin is due to the inactivation of UDP-GlcNAc-3-O-enolpyruvyltransferase (MurA), which catalyzes the first committed step in the biosynthesis of peptidoglycan, the main component of the bacterial cell wall (6,7).
NIH-PA Author ManuscriptNIH-PA Author Manuscript
NIH-PA Author ManuscriptFosfomycin belongs to a steadily growing family of natural products containing a C-P bond (8) (9). Members of this family, which include fosmydomicin (10) and bialaphos (11) are all derived from phosphoenolpyruvate (PEP, 2). The C-P bonds in these compounds are formed through an intramolecular rearrangement reaction catalyzed by PEP mutase, resulting in the conversion of PEP (2) to phosphopyruvate (PnPy, 3) ( Fig. 1) (12)(13)(14). Since the equilibrium between PEP and PnPy favors PEP, the decarboxylation catalyzed by the second enzyme in the biosynthetic pathway, PnPy decarboxylase, provides the driving force to shift the equilibrium toward C-P bond formation (15). The next two steps in the pathway...